S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
NASDAQ:REPL

Replimune Group (REPL) Stock Forecast, Price & News

$17.11
+0.61 (+3.70%)
(As of 09/29/2023 ET)
Compare
Today's Range
$15.67
$17.14
50-Day Range
$15.96
$21.32
52-Week Range
$15.51
$29.52
Volume
1.26 million shs
Average Volume
625,998 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.60

Replimune Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
201.6% Upside
$51.60 Price Target
Short Interest
Bearish
19.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.93mentions of Replimune Group in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$939,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.37) to ($3.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

373rd out of 972 stocks

Biological Products, Except Diagnostic Industry

59th out of 155 stocks


REPL stock logo

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Price History

REPL Stock News Headlines

Replimune Group (NASDAQ:REPL) Stock Price Down 3.2%
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
Replimune Group (NASDAQ: REPL)
Arvinas Holding Company (ARVN) Receives a Buy from Barclays
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
The Latest Analyst Ratings for Replimune Group
BTIG Keeps Their Buy Rating on Replimune Group (REPL)
EF Hutton Remains a Buy on Replimune Group (REPL)
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Company Calendar

Last Earnings
8/03/2023
Today
10/01/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
284
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$51.60
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+201.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-174,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.80 per share

Miscellaneous

Free Float
46,843,000
Market Cap
$1.01 billion
Optionable
Not Optionable
Beta
1.63
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Philip Astley-Sparke F.S.A. (Age 52)
    FSA, CEO, Interim CFO & Director
    Comp: $1.07M
  • Dr. Sushil Patel Ph.D. (Age 52)
    Chief Strategy Officer
    Comp: $665.05k
  • Dr. Robert Coffin Ph.D. (Age 58)
    Founder, Pres, Chief R&D Officer and Director
  • Dr. Colin A. Love Ph.D. (Age 65)
    Chief Operating Officer
  • Mr. Andrew Schwendenman (Age 47)
    Chief Accounting Officer & Treasurer
  • Dr. Pamela Esposito Ph.D. (Age 49)
    Chief Bus. Officer
  • Ms. Tanya N. Lewis M.S. (Age 52)
    Chief Devel. Operations Officer
  • Mr. Christopher Sarchi (Age 55)
    Chief Commercial Officer
  • Dr. Konstantinos Xynos M.B.A. (Age 57)
    M.D., Ph.D., Chief Medical Officer













REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price forecast for 2023?

5 analysts have issued 1 year target prices for Replimune Group's stock. Their REPL share price forecasts range from $34.00 to $70.00. On average, they anticipate the company's stock price to reach $51.60 in the next twelve months. This suggests a possible upside of 201.6% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2023?

Replimune Group's stock was trading at $27.20 on January 1st, 2023. Since then, REPL shares have decreased by 37.1% and is now trading at $17.11.
View the best growth stocks for 2023 here
.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.05. During the same quarter last year, the company earned ($0.78) EPS.

What ETFs hold Replimune Group's stock?

ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Horizon Kinetics Medical ETF (MEDX), First Trust Innovation Leaders ETF (ILDR).ALPS Medical Breakthroughs ETF (SBIO),

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $17.11.

How much money does Replimune Group make?

Replimune Group (NASDAQ:REPL) has a market capitalization of $1.01 billion. The company earns $-174,280,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.

How many employees does Replimune Group have?

The company employs 284 workers across the globe.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -